Zobrazeno 1 - 10 of 380 pro vyhledávání: '"Pavlopoulou, I."'
1
Akademický článek
Covid-19 pandemic? Mental health implications among nurses and Proposed interventions.
Autor: Georgousopoulou V; Department of Research, Quality Control and Continuing Education, University General Hospital of Alexandroupolis., Pervanidou P; First Department of Pediatrics, Medical School, National and Kapodistrian University of Athens, 'Agia Sophia' Children's Hospital., Perdikaris P; Department of Nursing School of Health Sciences University of Peloponnese., Vlachioti E; Department of Nursing, 'Aghia Sophia' Children's Hospital, Athens, Greece., Zagana V; Department of Nursing, 'Sotiria' General Hospital, Athens, Greece., Kourtis G; Department of Nursing, 'Sotiria' General Hospital, Athens, Greece., Pavlopoulou I; Department of Nursing, National and Kapodistrian University of Athens., Matziou V; Department of Nursing, National and Kapodistrian University of Athens.
Publikováno v: AIMS public health [AIMS Public Health] 2024 Mar 11; Vol. 11 (1), pp. 273-293. Date of Electronic Publication: 2024 Mar 11 (Print Publication: 2024).
Zobrazit plný text záznamu
3
Modelling SARS-CoV-2 Binding Antibody Waning 8 Months after BNT162b2 Vaccination
Autor: Hatzakis, A. Karabinis, A. Roussos, S. Pantazis, N. Degiannis, D. Chaidaroglou, A. Petsios, K. Pavlopoulou, I. Tsiodras, S. Paraskevis, D. Sypsa, V. Psichogiou, M.
Several lines of evidence suggest that binding SARS-CoV-2 antibodies such as anti-SARSCoV-2 RBD IgG (anti-RBD) and neutralising antibodies (NA) are correlates of protection against SARS-CoV-2, and the correlation of anti-RBD and NA is very high. The
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::f77349076cc42f9e604c78e36b4e5dcc
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:2999613
Zobrazit plný text záznamu
5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
6
Akademický článek
Systematic review of the efficacy, effectiveness and safety of cell-based seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age.
Autor: Jordan K; Health Technology Assessment, Health Information and Quality Authority (HIQA), Dublin, Ireland., Murchu EO; Health Technology Assessment, Health Information and Quality Authority (HIQA), Dublin, Ireland.; Department of Health Policy & Management, School of Medicine, Trinity College Dublin, Dublin, Ireland., Comber L; Health Technology Assessment, Health Information and Quality Authority (HIQA), Dublin, Ireland., Hawkshaw S; Health Technology Assessment, Health Information and Quality Authority (HIQA), Dublin, Ireland., Marshall L; Health Technology Assessment, Health Information and Quality Authority (HIQA), Dublin, Ireland., O'Neill M; Health Technology Assessment, Health Information and Quality Authority (HIQA), Dublin, Ireland., Teljeur C; Health Technology Assessment, Health Information and Quality Authority (HIQA), Dublin, Ireland., Harrington P; Health Technology Assessment, Health Information and Quality Authority (HIQA), Dublin, Ireland., Carnahan A; Public Health Agency of Sweden, Solna, Sweden.; European Centre for Disease Prevention and Control, EU/EEA National Immunisation Technical Advisory Group (NITAG) collaboration on newer and enhanced inactivated seasonal influenza vaccines, Stockholm, Sweden., Pérez-Martín JJ; European Centre for Disease Prevention and Control, EU/EEA National Immunisation Technical Advisory Group (NITAG) collaboration on newer and enhanced inactivated seasonal influenza vaccines, Stockholm, Sweden.; General Directorate of Public Health and Addictions, IMIB-Arrixaca, Murcia University, Murcia, Spain., Robertson AH; European Centre for Disease Prevention and Control, EU/EEA National Immunisation Technical Advisory Group (NITAG) collaboration on newer and enhanced inactivated seasonal influenza vaccines, Stockholm, Sweden.; Division of Infection Control and Environmental Health, Norwegian Institute of Public Health, Oslo, Norway., Johansen K; European Centre for Disease Prevention and Control, EU/EEA National Immunisation Technical Advisory Group (NITAG) collaboration on newer and enhanced inactivated seasonal influenza vaccines, Stockholm, Sweden.; European Centre for Disease Prevention and Control, Stockholm, Sweden., Jonge J; European Centre for Disease Prevention and Control, EU/EEA National Immunisation Technical Advisory Group (NITAG) collaboration on newer and enhanced inactivated seasonal influenza vaccines, Stockholm, Sweden.; Center for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands., Krause T; European Centre for Disease Prevention and Control, EU/EEA National Immunisation Technical Advisory Group (NITAG) collaboration on newer and enhanced inactivated seasonal influenza vaccines, Stockholm, Sweden.; Statens Serum Institut, Copenhagen, Denmark., Nicolay N; European Centre for Disease Prevention and Control, EU/EEA National Immunisation Technical Advisory Group (NITAG) collaboration on newer and enhanced inactivated seasonal influenza vaccines, Stockholm, Sweden.; European Centre for Disease Prevention and Control, Stockholm, Sweden., Nohynek H; European Centre for Disease Prevention and Control, EU/EEA National Immunisation Technical Advisory Group (NITAG) collaboration on newer and enhanced inactivated seasonal influenza vaccines, Stockholm, Sweden.; Finnish Institute for Health and Welfare, Helsinki, Finland., Pavlopoulou I; European Centre for Disease Prevention and Control, EU/EEA National Immunisation Technical Advisory Group (NITAG) collaboration on newer and enhanced inactivated seasonal influenza vaccines, Stockholm, Sweden.; School of Health Sciences, Faculty of Nursing, Pediatric Research Laboratory, National and Kapodistrian University of Athens, Athens, Greece.; National Advisory Committee on Immunisation, Hellenic Ministry of Health, Athens, Greece., Pebody R; European Centre for Disease Prevention and Control, EU/EEA National Immunisation Technical Advisory Group (NITAG) collaboration on newer and enhanced inactivated seasonal influenza vaccines, Stockholm, Sweden.; Institute of Epidemiology & Health, University College London, London, UK., Penttinen P; European Centre for Disease Prevention and Control, EU/EEA National Immunisation Technical Advisory Group (NITAG) collaboration on newer and enhanced inactivated seasonal influenza vaccines, Stockholm, Sweden.; European Centre for Disease Prevention and Control, Stockholm, Sweden., Soler-Soneira M; European Centre for Disease Prevention and Control, EU/EEA National Immunisation Technical Advisory Group (NITAG) collaboration on newer and enhanced inactivated seasonal influenza vaccines, Stockholm, Sweden.; Vigilancia de Enfermedades Prevenibles por Vacunación, Centro Nacional de Epidemiología, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, Madrid, Spain., Wichmann O; European Centre for Disease Prevention and Control, EU/EEA National Immunisation Technical Advisory Group (NITAG) collaboration on newer and enhanced inactivated seasonal influenza vaccines, Stockholm, Sweden.; Immunization Unit, Robert Koch-Institute, Berlin, Germany., Ryan M; Health Technology Assessment, Health Information and Quality Authority (HIQA), Dublin, Ireland.; Department of Pharmacology & Therapeutics, Trinity College Dublin, Trinity. Health Sciences, Dublin, Ireland.
Publikováno v: Reviews in medical virology [Rev Med Virol] 2023 May; Vol. 33 (3), pp. e2332. Date of Electronic Publication: 2022 Feb 08.
Zobrazit plný text záznamu
7
Akademický článek
Systematic review of the efficacy, effectiveness and safety of recombinant haemagglutinin seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age.
Autor: O Murchu E; Health Information and Quality Authority (HIQA), Dublin, Ireland.; Department of Health Policy & Management, School of Medicine, Trinity College Dublin, Dublin, Ireland., Comber L; Health Information and Quality Authority (HIQA), Dublin, Ireland., Jordan K; Health Information and Quality Authority (HIQA), Dublin, Ireland., Hawkshaw S; Health Information and Quality Authority (HIQA), Dublin, Ireland., Marshall L; Health Information and Quality Authority (HIQA), Dublin, Ireland., O'Neill M; Health Information and Quality Authority (HIQA), Dublin, Ireland., Ryan M; Health Information and Quality Authority (HIQA), Dublin, Ireland.; Department of Pharmacology & Therapeutics, Trinity Health Sciences, Trinity College Dublin, Dublin, Ireland., Teljeur C; Health Information and Quality Authority (HIQA), Dublin, Ireland., Carnahan A; Public Health Agency of Sweden, Solna, Sweden., Pérez JJ; General Directorate of Public Health and Addictions, IMIB-Arrixaca, Murcia University, Region of Murcia, Spain., Robertson AH; Division of Infection Control and Environmental Health, Norwegian Institute of Public Health, Oslo, Norway., Johansen K; European Centre for Disease Prevention and Control, Stockholm, Sweden., Jonge J; Center for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands., Krause T; Statens Serum Institut, Copenhagen, Denmark., Nicolay N; European Centre for Disease Prevention and Control, Stockholm, Sweden., Nohynek H; Finnish Institute for Health and Welfare, Helsinki, Finland., Pavlopoulou I; Pediatric Research Laboratory, School of Health Sciences, Faculty of Nursing, National Kapodistrian University of Athens, Athens, Greece.; National Advisory Committee on Immunisation, Hellenic Ministry of Health, Athens, Greece., Pebody R; Institute of Epidemiology & Health, University College London, London, UK., Penttinen P; European Centre for Disease Prevention and Control, Stockholm, Sweden., Soler-Soneira M; Vigilancia de Enfermedades Prevenibles por Vacunación, Centro Nacional de Epidemiología, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, Madrid, Spain., Wichmann O; Immunization Unit, Robert Koch-Institute, Berlin, Germany., Harrington P; Health Information and Quality Authority (HIQA), Dublin, Ireland.
Publikováno v: Reviews in medical virology [Rev Med Virol] 2023 May; Vol. 33 (3), pp. e2331. Date of Electronic Publication: 2022 Feb 02.
Zobrazit plný text záznamu
8
Akademický článek
Systematic review of the efficacy, effectiveness and safety of high-dose seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age.
Autor: Comber L; Health Information and Quality Authority (HIQA), Dublin, Ireland., O Murchu E; Health Information and Quality Authority (HIQA), Dublin, Ireland.; Department of Health Policy & Management, School of Medicine, Trinity College Dublin, Dublin, Ireland., Jordan K; Health Information and Quality Authority (HIQA), Dublin, Ireland., Hawkshaw S; Health Information and Quality Authority (HIQA), Dublin, Ireland., Marshall L; Health Information and Quality Authority (HIQA), Dublin, Ireland., O'Neill M; Health Information and Quality Authority (HIQA), Dublin, Ireland., Teljeur C; Health Information and Quality Authority (HIQA), Dublin, Ireland., Ryan M; Health Information and Quality Authority (HIQA), Dublin, Ireland.; Department of Pharmacology & Therapeutics, Trinity College Dublin, Trinity Health Sciences, Dublin, Ireland., Carnahan A; European Centre for Disease Prevention and Control, EU/EEA National Immunisation Technical Advisory Group (NITAG) Collaboration on Newer and Enhanced Inactivated Seasonal Influenza Vaccines, Solna, Sweden.; Public Health Agency of Sweden, Solna, Sweden., Pérez Martín JJ; European Centre for Disease Prevention and Control, EU/EEA National Immunisation Technical Advisory Group (NITAG) Collaboration on Newer and Enhanced Inactivated Seasonal Influenza Vaccines, Solna, Sweden.; General Directorate of Public Health and Addictions, IMIB-Arrixaca, Murcia University, Region of Murcia, Spain., Robertson AH; European Centre for Disease Prevention and Control, EU/EEA National Immunisation Technical Advisory Group (NITAG) Collaboration on Newer and Enhanced Inactivated Seasonal Influenza Vaccines, Solna, Sweden.; Division of Infection Control and Environmental Health, Norwegian Institute of Public Health, Oslo, Norway., Johansen K; European Centre for Disease Prevention and Control, EU/EEA National Immunisation Technical Advisory Group (NITAG) Collaboration on Newer and Enhanced Inactivated Seasonal Influenza Vaccines, Solna, Sweden.; European Centre for Disease Prevention and Control, Stockholm, Sweden., de Jonge J; European Centre for Disease Prevention and Control, EU/EEA National Immunisation Technical Advisory Group (NITAG) Collaboration on Newer and Enhanced Inactivated Seasonal Influenza Vaccines, Solna, Sweden.; National Institute for Public Health and the Environment, Center for Infectious Disease Control, Bilthoven, The Netherlands., Krause T; European Centre for Disease Prevention and Control, EU/EEA National Immunisation Technical Advisory Group (NITAG) Collaboration on Newer and Enhanced Inactivated Seasonal Influenza Vaccines, Solna, Sweden.; Statens Serum Institut, Copenhagen, Denmark., Nicolay N; European Centre for Disease Prevention and Control, EU/EEA National Immunisation Technical Advisory Group (NITAG) Collaboration on Newer and Enhanced Inactivated Seasonal Influenza Vaccines, Solna, Sweden.; European Centre for Disease Prevention and Control, Stockholm, Sweden., Nohynek H; European Centre for Disease Prevention and Control, EU/EEA National Immunisation Technical Advisory Group (NITAG) Collaboration on Newer and Enhanced Inactivated Seasonal Influenza Vaccines, Solna, Sweden.; Finnish Institute for Health and Welfare, Helsinki, Finland., Pavlopoulou I; European Centre for Disease Prevention and Control, EU/EEA National Immunisation Technical Advisory Group (NITAG) Collaboration on Newer and Enhanced Inactivated Seasonal Influenza Vaccines, Solna, Sweden.; Pediatric Research Laboratory, School of Health Sciences, Faculty of Nursing, National & Kapodistrian University of Athens, Goudi, Greece.; National Advisory Committee on Immunisation, Hellenic Ministry of Health, Athens, Greece., Pebody R; European Centre for Disease Prevention and Control, EU/EEA National Immunisation Technical Advisory Group (NITAG) Collaboration on Newer and Enhanced Inactivated Seasonal Influenza Vaccines, Solna, Sweden.; Institute of Epidemiology & Health, University College London, London, UK., Penttinen P; European Centre for Disease Prevention and Control, EU/EEA National Immunisation Technical Advisory Group (NITAG) Collaboration on Newer and Enhanced Inactivated Seasonal Influenza Vaccines, Solna, Sweden.; European Centre for Disease Prevention and Control, Stockholm, Sweden., Soler-Soneira M; European Centre for Disease Prevention and Control, EU/EEA National Immunisation Technical Advisory Group (NITAG) Collaboration on Newer and Enhanced Inactivated Seasonal Influenza Vaccines, Solna, Sweden.; Vigilancia de Enfermedades Prevenibles por Vacunación, Centro Nacional de Epidemiología, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, Madrid, Spain., Wichmann O; European Centre for Disease Prevention and Control, EU/EEA National Immunisation Technical Advisory Group (NITAG) Collaboration on Newer and Enhanced Inactivated Seasonal Influenza Vaccines, Solna, Sweden.; Immunization Unit, Robert Koch-Institute, Berlin, Germany., Harrington P; Health Information and Quality Authority (HIQA), Dublin, Ireland.
Publikováno v: Reviews in medical virology [Rev Med Virol] 2023 May; Vol. 33 (3), pp. e2330. Date of Electronic Publication: 2022 Feb 04.
Zobrazit plný text záznamu
9
Akademický článek
Systematic review of the efficacy, effectiveness and safety of MF59 ® adjuvanted seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age.
Autor: O Murchu E; Health Information and Quality Authority (HIQA), Dublin, Ireland.; Department of Health Policy & Management, School of Medicine, Trinity College Dublin, Dublin, Ireland., Comber L; Health Information and Quality Authority (HIQA), Dublin, Ireland., Jordan K; Health Information and Quality Authority (HIQA), Dublin, Ireland., Hawkshaw S; Health Information and Quality Authority (HIQA), Dublin, Ireland., Marshall L; Health Information and Quality Authority (HIQA), Dublin, Ireland., O'Neill M; Health Information and Quality Authority (HIQA), Dublin, Ireland., Ryan M; Health Information and Quality Authority (HIQA), Dublin, Ireland.; Department of Pharmacology & Therapeutics, Trinity College Dublin, Trinity Health Sciences, Dublin, Ireland., Teljeur C; Health Information and Quality Authority (HIQA), Dublin, Ireland., Carnahan A; Public Health Agency of Sweden, Solna, Sweden., Pérez JJ; General Directorate of Public Health and Addictions, IMIB-Arrixaca. Murcia University, Region of Murcia, Spain., Robertson AH; Division of Infection Control and Environmental Health, Norwegian Institute of Public Health, Oslo, Norway., Johansen K; European Centre for Disease Prevention and Control, Solna, Sweden., Jonge J; Center for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands., Krause T; Statens Serum Institut, Copenhagen, Denmark., Nicolay N; European Centre for Disease Prevention and Control, Solna, Sweden., Nohynek H; Finnish Institute for Health and Welfare, Helsinki, Finland., Pavlopoulou I; Pediatric Research Laboratory, School of Health Sciences, Faculty of Nursing National and Kapodistrian University of Athens, Athens, Greece.; National Advisory Committee on Immunisation, Hellenic Ministry of Health, Athens, Greece., Pebody R; Institute of Epidemiology & Health, University College London, London, UK., Penttinen P; European Centre for Disease Prevention and Control, Solna, Sweden., Soler-Soneira M; Vigilancia de Enfermedades Prevenibles por Vacunación, Centro Nacional de Epidemiología, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, Madrid, Spain., Wichmann O; Immunization Unit, Robert Koch-Institute, Berlin, Germany., Harrington P; Health Information and Quality Authority (HIQA), Dublin, Ireland.
Publikováno v: Reviews in medical virology [Rev Med Virol] 2023 May; Vol. 33 (3), pp. e2329. Date of Electronic Publication: 2022 Feb 10.
Zobrazit plný text záznamu
10
Epidemiology of nonalcoholic fatty liver disease in europe: A systematic review and meta-analysis
Autor: Cholongitas, E. Pavlopoulou, I. Papatheodoridi, M. Markakis, G.E. Bouras, E. Haidich, A.-B. Papatheodoridis, G.
Background Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the developed countries. The aim of this study was to evaluate the NAFLD prevalence in European adults and children/adolescents of the general po
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::6a9833db7ae426e9444e6f28ee45afba
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3103120
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje